Syncona Ltd announced that it has committed $42.5 million (£33.5 million) to a $170 million (£134 million) Series B financing of its portfolio company Beacon Therapeutics, a leading ophthalmic gene therapy company
Tag: Beacon Therapeutics
Syncona launches Beacon Therapeutics with £96 million financing to develop ophthalmic gene therapies
LONDON, UK: London-based healthcare company Syncona Ltd has announced the launch of Beacon Therapeutics Holdings Limited (Beacon Therapeutics), a leading ophthalmic gene therapy company. The company aims to restore and improve the vision of patients with retinal diseases. The launch was made possible through a £96 million ($134 million) Series A financing round. Beacon Therapeutics…